Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. on Bloomberg TV on August 17, 2024. Soligenix, a late-stage biopharmaceutical company, highlights its strong portfolio with products targeting a potential $2 billion in annual global sales. Key developments include:
1. HyBryte™, a photodynamic therapy for cutaneous T-cell lymphoma, with positive Phase 3 results and $250 million market potential.
2. SGX302 for psoriasis in Phase 2a trial, with over $1 billion market potential.
3. SGX945 for Behçet's Disease, entering Phase 2a later this year.
4. Collaborations and non-dilutive funding supporting vaccine development, including a filovirus vaccine program showing complete protection in non-human primates.
RedChip Companies trasmetterà interviste con Soligenix Inc. (Nasdaq:SNGX) e American Resources Corp. su Bloomberg TV il 17 agosto 2024. Soligenix, un'azienda biofarmaceutica in fase avanzata, mette in evidenza il suo forte portafoglio con prodotti mirati a un potenziale di $2 miliardi di vendite globali annuali. I principali sviluppi includono:
1. HyBryte™, una terapia fotodinamica per il linfoma T-cutaneo, con risultati positivi di Fase 3 e un potenziale di mercato di $250 milioni.
2. SGX302 per la psoriasi in fase di sperimentazione 2a, con oltre $1 miliardo di potenziale di mercato.
3. SGX945 per la malattia di Behçet, che entrerà nella fase 2a entro la fine di quest'anno.
4. Collaborazioni e finanziamenti non diluitivi a sostegno dello sviluppo di vaccini, incluso un programma di vaccini contro i filovirus che ha mostrato una protezione completa nei primati non umani.
RedChip Companies presentará entrevistas con Soligenix Inc. (Nasdaq:SNGX) y American Resources Corp. en Bloomberg TV el 17 de agosto de 2024. Soligenix, una empresa biofarmacéutica en etapa avanzada, resalta su sólido portafolio con productos dirigidos a un potencial de $2 mil millones en ventas globales anuales. Los principales desarrollos incluyen:
1. HyBryte™, una terapia fotodinámica para el linfoma de células T cutáneas, con resultados positivos de Fase 3 y un potencial de mercado de $250 millones.
2. SGX302 para la psoriasis en un ensayo de Fase 2a, con un potencial de mercado de más de $1 mil millones.
3. SGX945 para la enfermedad de Behçet, que ingresará en la fase 2a más adelante este año.
4. Colaboraciones y financiamiento no dilutivo que respaldan el desarrollo de vacunas, incluido un programa de vacunas contra filovirus que muestra una protección completa en primates no humanos.
RedChip Companies는 2024년 8월 17일 Bloomberg TV에서 Soligenix Inc. (Nasdaq:SNGX) 및 American Resources Corp.와의 인터뷰를 방영할 예정입니다. Soligenix는 임상 마지막 단계의 생명공학 회사로 연간 20억 달러의 글로벌 판매 잠재력을 목표로 하는 강력한 포트폴리오를 강조합니다. 주요 개발 사항은 다음과 같습니다:
1. HyBryte™, 피부 T세포 림프종을 위한 광선 치료제로, 3상에서 긍정적인 결과를 보였으며 2억 5천만 달러의 시장 잠재력을 가지고 있습니다.
2. 2a상 시험 중인 건선 치료제 SGX302, 10억 달러 이상의 시장 잠재력을 보유하고 있습니다.
3. 올해 말 2a상으로 들어갈 SGX945, 베체트병 치료제입니다.
4. 비희석 자금을 통해 백신 개발을 지원하는 협력 관계, 비인간 영장류에서 완전한 보호를 보이는 필로바이러스 백신 프로그램 포함.
RedChip Companies diffusera des interviews avec Soligenix Inc. (Nasdaq:SNGX) et American Resources Corp. sur Bloomberg TV le 17 août 2024. Soligenix, une entreprise biopharmaceutique en phase avancée, met en avant son solide portefeuille de produits visant un potentiel de 2 milliards de dollars de ventes annuelles mondiales. Les développements clés incluent :
1. HyBryte™, une thérapie photodynamique pour le lymphome T cutané, avec des résultats positifs en phase 3 et un potentiel de marché de 250 millions de dollars.
2. SGX302 pour le psoriasis en essai de phase 2a, avec un potentiel de marché de plus d'un milliard de dollars.
3. SGX945 pour la maladie de Behçet, qui passera à la phase 2a plus tard cette année.
4. Collaborations et financements non dilutifs soutenant le développement de vaccins, y compris un programme de vaccin contre les filovirus montrant une protection complète chez les primates non humains.
RedChip Companies wird am 17. August 2024 Interviews mit Soligenix Inc. (Nasdaq:SNGX) und American Resources Corp. auf Bloomberg TV ausstrahlen. Soligenix, ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, hebt sein starkes Portfolio mit Produkten hervor, die ein potenzielles jährliches Verkaufsvolumen von 2 Milliarden US-Dollar anvisieren. Zu den wichtigsten Entwicklungen gehören:
1. HyBryte™, eine photodynamische Therapie für kutanen T-Zell-Lymphom, mit positiven Ergebnissen der Phase 3 und einem Marktpotenzial von 250 Millionen US-Dollar.
2. SGX302 für Psoriasis in der Phase 2a-Studie, mit einem Marktpotenzial von über 1 Milliarde US-Dollar.
3. SGX945 für die Behçet-Erkrankung, die später in diesem Jahr in die Phase 2a eintreten wird.
4. Kooperationen und nicht verwässernde Finanzierungen zur Unterstützung der Impfstoffentwicklung, einschließlich eines Programms für ein Filovirus-Impfstoff, das vollständigen Schutz bei nichtmenschlichen Primaten zeigt.
- HyBryte™ demonstrated positive results in a Phase 3 study for cutaneous T-cell lymphoma
- Strong portfolio targeting potential $2 billion in annual global sales
- Non-dilutive funding and NIH grants supporting vaccine development
- Filovirus vaccine program showed complete protection in non-human primates
- FDA granted orphan drug designations for certain vaccine candidates
- Follow-up confirmatory Phase 3 study for HyBryte™ still needed
- SGX302 and SGX945 are still in early clinical stages (Phase 2a)
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
Soligenix: https://www.redchip.com/assets/access/sngx_access
American Resources: https://www.redchip.com/assets/access/arec_access
In an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Soligenix, a late-stage biopharmaceutical company, showcases a strong portfolio with several products in advanced clinical stages, targeting a potential
Mark Jensen, Chairman and CEO of American Resources, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. American Resources Corp. is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. American Resources is monetizing its carbon assets while simultaneously capitalizing on the wealth of opportunities for the rapid growth of its ReElement Technologies division, which recently became the first domestic, commercial producer of isolated and high-purity rare-earth elements. It is estimated that approx.
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
About American Resources
American Resources Corporation is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated.
American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit americanresourcescorp.com or connect with the Company on Facebook, Twitter, and LinkedIn.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
What is Soligenix's (SNGX) lead product and its market potential?
What other key products are in Soligenix's (SNGX) pipeline?
Has Soligenix (SNGX) received any significant recognition from the FDA?
When will the Soligenix (SNGX) interview air on Bloomberg TV?
